Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gujarat Kidney And Super Speciality's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was ₹0.81.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2.32.
During the past 12 months, Gujarat Kidney And Super Speciality's average earnings per share (NRI) Growth Rate was 108.50% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 43.50% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
NSE:GKSL'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 43.5 Med: 43.5 Max: 43.5
Current: 43.5
During the past 4 years, Gujarat Kidney And Super Speciality's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 43.50% per year. The lowest was 43.50% per year. And the median was 43.50% per year.
NSE:GKSL's 3-Year EPS without NRI Growth Rate is ranked better than 84.71% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 11.55
vs NSE:GKSL: 43.50
Gujarat Kidney And Super Speciality (NSE:GKSL) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Gujarat Kidney And Super Speciality EPS without NRI Related Terms
Gujarat Kidney And Super Speciality EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality EPS without NRI Chart
Gujarat Kidney And Super Speciality Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EPS without NRI
0.84
1.23
1.19
2.49
Gujarat Kidney And Super Speciality Quarterly Data
NSE:GKSL vs HCA, THC, DVA: EPS without NRI Comparison
For the Medical Care Facilities subindustry, Gujarat Kidney And Super Speciality's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Kidney And Super Speciality PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Gujarat Kidney And Super Speciality's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Gujarat Kidney And Super Speciality's PE Ratio without NRI falls into.
Gujarat Kidney And Super Speciality EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality (NSE:GKSL) has a EPS without NRI of ₹2.32 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Gujarat Kidney And Super Speciality and its competitors. According to the industry distribution chart, Gujarat Kidney And Super Speciality ranks #78 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 15.3%.
Is Gujarat Kidney And Super Speciality's EPS without NRI too high?
Gujarat Kidney And Super Speciality's current EPS without NRI is ₹2.32. Based on the distribution chart, Gujarat Kidney And Super Speciality ranks #78 out of 510 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Gujarat Kidney And Super Speciality has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Kidney And Super Speciality's EPS without NRI compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Gujarat Kidney And Super Speciality ranks #78 out of 510 companies for EPS without NRI. This places Gujarat Kidney And Super Speciality in the top 15% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 11.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.55, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Gujarat Kidney And Super Speciality and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Kidney And Super Speciality's current EPS without NRI is ₹2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Kidney And Super Speciality stock overvalued right now?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a current EPS without NRI of ₹2.32. The current EPS without NRI is ₹2.32. Gujarat Kidney And Super Speciality's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Gujarat Kidney And Super Speciality (NSE:GKSL), the current EPS without NRI is ₹2.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gujarat Kidney And Super Speciality Business Description
Gujarat Kidney And Super Speciality Ltd is engaged in the business of operating a chain of mid-sized multispeciality hospitals in central Gujarat and providing integrated healthcare services, with a focus on secondary and tertiary care. It offers a range of healthcare services, including General Medicine, General Surgery, Laparoscopic Surgery, Urology, Cardiology, Nephrology, and many more. The company operates in a single segment, namely Medical and Healthcare Services. It generates a substantial portion of revenue from its services to inpatients. Geographically, it operates only in India.
18GF Score
Get the complete analysis for NSE:GKSL
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKSL has been successfully added to your 
